Sign inJoin waitlistJoin the waitlist

MH

Martee Hensley

Associate Vice Chair, Academic Affairs · New York Presbyterian Hospital

Credentials: · · ·

History

New York Presbyterian Hospital
Present

New York Presbyterian Hospital
1992–1994
Internal Medicine
New York Presbyterian Hospital
1989–1992
Harvard School of Public Health
Duke University School of Medicine
1985–1989

Research

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
New England Journal of Medicine · 2002 · 960 citations
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
New England Journal of Medicine · 2003 · 955 citations
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized…
Journal of Clinical Oncology · 2016 · 655 citations

CA
Carol Aghajanian
55 papers
PS
Paul Sabbatini
48 papers
DS
David Spriggs
38 papers
NA
Nadeem Abu-Rustum
33 papers
RB
Richard Barakat
33 papers
RS
Robert Soslow
33 papers
ML
Mario Leitao
31 papers · 5 as a resident
Dennis Chi
28 papers
SC
Sarah Chiang
27 papers
JK
Jason Konner
23 papers
WT
William Tew
20 papers
KA
Kaled Alektiar
19 papers

Clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Principal investigator · Terminated · Phase 3
Gynecologic Oncology Group
2012–2019
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Principal investigator · Terminated · Phase 3
National Cancer Institute (NCI)
2009–2015
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2006–2012
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Principal investigator · Completed · Phase 2
Sarcoma Alliance for Research through Collaboration
2006–2012